

bjclub

breastJournalClub

20-21 NOVEMBRE 2015
TRIESTE

PREMIO MIGLIORE STUDIO ITALIANO
VALENTINA GUARNERI

PREMIO SPECIALIZZANDO PER MIGLIORE STUDIO
MARTA BONOTTO

PRESENTAZIONE GERMAN BREAST GROUP
MICHAEL UNTCH

BOARD

Alberto Bottini
Francesco Cognetti
Pierfranco Conte
Michelino De Laurentiis
Sabino De Placido
Luigi Dogliotti
Luca Gianni
Giorgio Mustacchi
Paolo Pronzato
Fabio Puglisi

PROGETTO ECM E SEGRETERIA ORGANIZZATIVA



Via Pagliari, 4 26100 Cremona
tel 0372 23310 fax 0372 569605
info@overgroup.eu
www.overgroup.eu

CON IL CONTRIBUTO INCONDIZIONATO DI



ECM

Il corso ha ottenuto nr. 7 CREDITI
ECM per le seguenti discipline:
Biologia, Oncologia, Radioterapia,
Chirurgia Generale,
Anatomia Patologica,
Patologia Clinica

CON IL PATROCINIO
DELL'ASSOCIAZIONE ITALIANA
DI ONCOLOGIA MEDICA



bjclub
breastJournalClub

20-21 NOVEMBRE 2015
TRIESTE

STARHOTELS SAVOIA EXCELSIOR PALACE
Riva del Mandracchio, 4

PRESIDENTI DEL CONGRESSO
GIORGIO MUSTACCHI
FABIO PUGLISI

OSPITE INTERNAZIONALE
OLIVIA PAGANI

20 NOVEMBER 2015

**15:15
NANOTECHNOLOGY IN BREAST
CANCER**

A. Bottini

FOCUS ON GeparSepto

Invited Speaker: Michael Untch

16:00

Welcome and introduction

16:15

BEST INTERNATIONAL STUDY

G. Mustacchi, F. Puglisi

16:20

Adjuvant Exemestane with Ovarian
Suppression in Premenopausal Breast
Cancer

O. Pagani

16:50

Discussion

P.F. Conte

17:00

BEST "MADE IN ITALY" STUDY

F. Cognetti

17:05

Double-blind, placebo-controlled, multi-center, randomized, phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer

V. Guarneri

17:30

Discussion

P. Pronzato

17:45

**BEST STUDY BY ITALIAN
POSTGRADUATE STUDENTS**

S. De Placido, A. Sapino

17:50

Measures of outcome in metastatic breast cancer: insights from a real-world scenario

M. Bonotto

18:20

Discussion

M. De Laurentiis

18:35

Fine lavori

21 NOVEMBER 2015

09:00

**BEST RESEARCH BY YOUNG
INVESTIGATORS**

V. Adamo, A. Frassoldati

Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis

M. Giuliano

DISCUSSANT: C. Tondini

Long-term outcome results of the phase III PROMISE-GIM6 study evaluating the role of LHRH analog (LHRHa) during chemotherapy (CT) as a strategy to reduce ovarian failure in early breast cancer (BC) patients

M. Lambertini

DISCUSSANT: L. Del Mastro

10:00

PEARLS FROM ASCO AND ESMO 2015

G. Bianchini

10:30

ONGOING RESEARCH: EARLY DISEASE

A. Fabi, M. Mansutti

ADAPT

Adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in

early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trial

G. Arpino

ETNA

Neoadjuvant chemotherapy with nab-paclitaxel in women with HER2-negative high-risk breast cancer nab-paclitaxel 150 mg/m² day 1, 8, 15 for 4 cycles 28 days followed by AC or FEC for 4 cycles vs Weekly paclitaxel for 4 cycles followed by AC or FEC for 4 cycles both followed by surgery

M. Zambetti

PER-ELISA

PERtuzumab-trastuzumab plus lEtrozoLe In endocrine Sensitive breast cancer: a phase II neoAdjuvant study

M.V. Dieci

11:15

Coffee break

11:30

**ONGOING RESEARCH: ADVANCED
DISEASE**

MT. Ionta, E. Simoncini

GOIM

A multicenter phase II trial of nab-paclitaxel and capecitabine as first

line treatment in HER2-negative metastatic breast cancer

S. Cinieri

EFFECT

Evaluation of the efficacy and impact on patient functioning of two doses of nab-paclitaxel in elderly (>65 yrs) breast cancer patients

L. Biganzoli

TNACITY

Phase 2/3, multi-center, open-label, randomized study of weekly Nab-paclitaxel in combination with gemcitabine or carboplatin, vs gemcitabine / carboplatin, as first-line treatment in TNMBC Abraxane 125mg/ m², Gemcitabine 1000mg/m², Carboplatin AUC2 days 1,8 cycles 21 days

S. Spazzapan

ABRAMYO

Phase I-II, multicenter open label study in patients with previously untreated metastatic breast cancer

Nab-paclitaxel 100_125 mg/ m² and with LDox 20_25 mg/ m² will be administered on days 1, 8, 15 of a 28-day cycle until disease progression

P. Papaldo

SNAP

A randomized phase II study evaluating

three different schedules of nab-paclitaxel as maintenance therapy

A. Gennari

GIM 13 - AMBRA

Longitudinal, observational study on the choices of chemotherapy for HER2-negative metastatic breast cancer in the clinical practice

G. Mustacchi

REAL WORD STUDY

Moving Beyond Clinical Trials: a real world multi center Italian experience with albumin-bound paclitaxel (nab-paclitaxel) in metastatic breast cancer.

E. Simoncini

TACT

A phase II randomized, open-label study evaluating the addition of trastuzumab to (nabTM)-paclitaxel as first line treatment in primary HER2 negative metastatic breast cancer patients with HER2 positive Circulating Tumor Cells (CTCs)

D. Generali

ROUND TABLE

A. Bottini, F. Cognetti, P.F. Conte, M. De Laurentiis, S. De Placido, L. Dogliotti, L. Gianni, G. Mustacchi, P. Pronzato, F. Puglisi

13:30

Conclusions

